M3, Inc. · TSE:2413
M3 — FY2020 Q2 Earnings Presentation
27 slides from M3's earnings presentation, Oct 30, 2020

Slide 1: M3, Inc. Presentation Material October 2020
M3, Inc. Presentation Material October 2020 Copyright © 2020 M3, Inc. All rights reserved.

Slide 2: Forward-looking statements disclaimer
The following presentation contains forecasts, future plans, management targets and other forward-looking projections relating to M3, Inc. and/or its group. These statements are drawn from assumptions of future events based on data currently available to us, and there exist possibilities that such a

Slide 3: FY2020 Q2 Consolidated Results Summary
FY2020 Q2 Consolidated Results Summary Copyright © 2020 M3, Inc. All rights reserved. 2

Slide 4: FY2020 Q2 Consolidated Results
FY2020 Q2 Consolidated Results IFRS (mn yen) FY2019 Q2 FY2020 Q2 YoY Sales 61,545 75,022 +22% +61% Operating Profit 16,549 23,931 +45% growth excluding impacts such as Pre-tax Profit 16,597 23,943 +44% stock sales and valuation changes Net Profit 11,312 16,587 +47% Profits increased 41% in Q1, and 8

Slide 5: FY2020 Q2 Consolidated Results by Segment
FY2020 Q2 Consolidated Results by Segment FY2019 FY2020 (mn yen) YoY Q2 Q2 +106% YoY profit growth Medical Sales 22,269 30,915 +39% excluding impact such as stock Platform Profit 7,404 13,748 +86% sales Evidence Sales 10,739 9,603 -11% Solution Profit 2,209 1,631 -26% Temporary Domestic demand decre

Slide 6: FY2020 Q2 Consolidated Operating Profit Contribution Breakdown
FY2020 Q2 Consolidated Operating Profit Contribution Breakdown (mn yen) Large Recovery Temporary APAC from neg demand decrease Demand growth COVID-19 due to COVID-19 expansion from impacts Stock valuation pharma changes companies 472 -204 -326 -578 2,416 -741 Investment in LINE Healthcare increased,

Slide 7: FY2020 Q2 Overview
FY2020 Q2 Overview COVID-19 Impact Medical Accelerated digital transformation in pharma marketing Platform Marketing service orders grew 2.5x yoy in H1 ++ Evidence Orders backlog remained steady at 23.5 bn yen despite _ Solution partial halts in projects Career Dampened demand from both phys

Slide 8: COVID-19 Impact on M3
COVID-19 Impact on M3 Copyright © 2020 M3, Inc. All rights reserved. 7

Slide 9: COVID-19 Impact on M3
COVID-19 Impact on M3 Structural changes in pharmaceutical marketing Structural changes in clinical scene… telemedicine, AI diagnostics Clinical Trials Y’s Rehabilitation Center Hospital Management Support Home Care Nursing Career Copyright © 2020 M3, Inc. All rights reserved. 8

Slide 10: COVID-19 Impact on M3
COVID-19 Impact on M3 Structural changes in pharmaceutical marketing Structural changes in clinical scene… telemedicine, AI diagnostics Clinical Trials Y’s Rehabilitation Center Hospital Management Support Home Care Nursing Career Copyright © 2020 M3, Inc. All rights reserved. 9

Slide 11: m3.com Site Access Increase
m3.com Site Access Increase COVID-19 Related Information Provision m3.com Access Increase (% yoy) 160% Focused delivery of related news 150% 140% Proactive 130% information 120% exchange across 110% PtoP communities 100% Expert webinars 90% regarding COVID- H1 H2 H1 H2 H1 19 examination FY18 FY19 FY

Slide 12: COVID-19 Impact on M3
COVID-19 Impact on M3 Structural changes in pharmaceutical marketing Structural changes in clinical scene… telemedicine, AI diagnostics Clinical Trials Y’s Rehabilitation Center Hospital Management Support Home Care Nursing Career Copyright © 2020 M3, Inc. All rights reserved. 11

Slide 13: Hospital Measures Against COVID-19
Hospital Measures Against COVID-19 Marketing Support Thorough nosocomial infection prevention 95% measures 92% 91% MR visitation restriction 82% Prompt procurement of COVID-19 treatments 88% (including unapproved drugs) 33% 76% Procurement of personal protective equipment 78% Procurement of drugs wi

Slide 14: Marketing Support Service Orders Over 2.5x
Marketing Support Service Orders Marketing Support Marketing Support Service Orders Rapid demand increase from pharmaceutical companies due to Over COVID-19 2.5x Sales team fortification (+78% yoy including external resource utilization) contributing to larger projects Fortification of project

Slide 15: LINE Healthcare Expansion
LINE Healthcare Expansion Telemedicine Over 7.8 million “friends” (since launch in Dec 2019) Reimbursable online consultation service “LINE Doctor” scheduled for launch in November Copyright © 2020 M3, Inc. All rights reserved. 14

Slide 16: "LINE Doctor" Adoption Intent
“LINE Doctor” Adoption Intent Telemedicine Of doctors that plan to offer online consultations, 83% wish to use “LINE Doctor” Would use even if more expensive than competitors Would not like to use LINE Doctor Will offer online 17% Would use if consultations 61% cheaper than or the equal to competito

Slide 17: Launch of AI Platform Business
Launch of AI Platform Business AI NOBORI Cloud Business alliance with NOBORI ・・・ providing medical cloud services Secure image AI diagnosed Connectivity with any upload image PACS (medical image download management system) Medical Site Multiple AI image PACS diagnostic algorithms will be on-bo

Slide 18: AI Platform Algorithms
AI Platform Algorithms AI Pulmonary VUNO Med®-LungCT nodule shadow by Pulmonary EIRL Chest nodule nodules by COVID-19 Ali-M3 pneumonia by & Cerebral EIRL aneurysm aneurysm by New algorithms continue to onboard M3’s AI platform Copyright © 2020 M3, Inc. All rights reserved. 17

Slide 19: Rapid Increase in AI Projects (1/2)
Rapid Increase in AI Projects (1/2) AI M3 Services Company Therapy Area M3 Respiratory M3 Diabetic Retinopathy M3 M3 Ostheoperosis Lead M3 Medical institution (overseas) M3 COVID-19 M3 Lung Cancer AI Venture Thyroid Echo AI Venture Radiation Diagnosis AI Venture Coronary Artery AI Venture Coronary A

Slide 20: Rapid Increase in AI Projects (2/2)
Rapid Increase in AI Projects (2/2) AI M3 Services Company Therapy Area AI Venture Influenza AI Venture Unruptured Cerebral Aneurysm AI Venture Insomnia Academia Respiratory AI Venture Gastrointestinal Device Maker Fundoscopy Device Maker Gastrointestinal Surgery AI Venture Alzheimers AI Venture Flu

Slide 21: COVID-19 Impact on M3 (Negative)
COVID-19 Impact on M3 (Negative) Q1 Assumptions Q2 Assumptions Clinical Trials (Evidence Solution) – Temporary suspension in trial execution – Potential for demand expansion from new R&D activity once conditions normalize Initiation of COVID-19 – COVID-19 vaccine related trials related vaccine tri

Slide 22: US Clinical Trial Business Update
US Clinical Trial Business Update COVID-19 Related Trials Vaccine Vaccine COVID-19 related trial orders: several billion yen Vaccine* Current high pace expected to remain high Treatment for the fiscal year Vaccine Further upside potential still exists Treatment … Post COVID-19 pipeline also healt

Slide 23: COVID-19 Impact on M3
COVID-19 Impact on M3 Structural changes in pharmaceutical marketing Structural changes in clinical scene… telemedicine, AI diagnostics Clinical Trials Y’s Rehabilitation Center Hospital Management Support Home Care Nursing Career Copyright © 2020 M3, Inc. All rights reserved. 22

Slide 24: Change in Growth Pace (start point: pre-COVID)
Change in Growth Pace (start point: pre-COVID) Business Trend Image Aggregate Impact Larger positive impact than expected Current outlook Initial outlook Structural changes progressing faster than expected Short term neutral overall, structural changes expected to be largely positive for the mid to

Slide 25: M3 Growth Strategy
M3 Growth Strategy Copyright © 2020 M3, Inc. All rights reserved. 24

Slide 26: Business Scope Expansion and Growth Potential
Business Scope Expansion and Growth Potential 2010 2014 2018 2022 Country : 3 → 5 (1.5x) → 10 (3x) → Similar pace Business Types : 6 → 10 (1.5x) → 26 (4x) → of growth expected Business Units (Type x Country) : 10 → 18 (2x) → 41 (4x) → over the next 4 years Sales (bn yen) : 14.0 → 37.0 (2.5x) → 94.5

Slide 27: Annual Results
Annual Results Sales Operating Profit & Net Profit 130,973 34,337 (mn yen) (mn yen) 30,800 113,059 Operating Profit 27,486 94,471 25,050 Net Profit 24,153 21,346 78,143 20,022 19,225 64,660 16,938 16,061 51,346 13,738* 13,493 10,428 36,759 9,294 8,878* 7,648 26,007 6,031 19,040 5,598 4,803 4,492 14,
Source: Internet Archive copy of corporate.m3.com
More decks from M3, Inc.
Investor Presentation (November 2026)8 slides · Nov 20, 2026
H1 FY2026 Earnings Presentation44 slides · Nov 4, 2026
Q2 FY2026 Earnings Presentation44 slides · Nov 4, 2026
Q1 FY2026 Earnings Presentation42 slides · Aug 6, 2026
Merger or Acquisition (June 2026)14 slides · Jun 5, 2026
FY2025 Earnings Presentation54 slides · May 1, 2026